Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.8 HKD | -2.02% | -2.58% | +1.80% |
Apr. 15 | Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug | MT |
Apr. 15 | Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.80% | 617M | |
+33.19% | 693B | |
+29.39% | 584B | |
-3.10% | 372B | |
+20.41% | 332B | |
+6.84% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+9.13% | 168B |
- Stock Market
- Equities
- 1477 Stock
- News Ocumension Therapeutics
- Ocumension Therapeutics' Eye Drug Completes Clinical Trials, to Apply for NDA Soon